1. Academic Validation
  2. Jiawei Buzhong Yiqi Decoction attenuates polycystic ovary syndrome through regulating kisspeptin-GPR54-AKT-SHBG system

Jiawei Buzhong Yiqi Decoction attenuates polycystic ovary syndrome through regulating kisspeptin-GPR54-AKT-SHBG system

  • Phytomedicine. 2024 Oct:133:155931. doi: 10.1016/j.phymed.2024.155931.
Runan Hu 1 Yuli Geng 1 Yanjing Huang 1 Zhuo Liu 1 Fan Li 1 Kunkun Song 2 Wenwen Ma 2 Haoxu Dong 2 Mingmin Zhang 2 Ting Lei 3 Yufan Song 2 Zhuo Zhang 4
Affiliations

Affiliations

  • 1 Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
  • 2 Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
  • 3 Sino-German Neuro-Oncology Molecular Laboratory, Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
  • 4 Sino-German Neuro-Oncology Molecular Laboratory, Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: zhangzhuo@tjh.tjmu.edu.cn.
Abstract

Background: Polycystic ovary syndrome (PCOS) is one of the most common reproductive endocrine disorders. Accumulated evidence has suggested the indispensable role of kisspeptin-G protein-coupled receptor (GPR54) system and SHBG in development of PCOS. However, potential mechanisms and their relationship are unclear. Jiawei Buzhong Yiqi Decoction (JWBZYQ) has been reported to ameliorate obese PCOS. Whereas, potential mechanisms remain elusive.

Purpose: To determine whether JWBZYQ attenuates PCOS by regulating the kisspeptin-GPR54 system and SHBG production. And to explore potential mechanisms.

Methods: An overweight PCOS rat model was developed with testosterone propionate (TP) and high-fat diet (HFD). The efficacy of JWBZYQ was assessed by tracking changes in weight, estrous cycle, ovarian morphology, and serum sex hormone levels. Additionally, kisspeptin-GPR54 system expression in multiple organs and PI3K-AKT pathway activity in liver of different rats were detected. Modifications in SHBG production were also measured. Kisspeptin54 was administered to establish a cellular model. The levels of Akt phosphorylation and SHBG protein within HepG2 cells were analyzed. Finally, confirmatory studies were performed using Akt phosphorylation activator and inhibitor.

Results: JWBZYQ effectively attenuated the overweight, disrupted estrous cycle, altered sex hormone levels, and aberrant ovarian morphology in PCOS rats. Meanwhile, PCOS rats exhibited elevated levels of kisspeptin and GPR54, along with reduced SHBG levels, which could be reversed by JWBZYQ. These alterations might be connected with the activation of Akt phosphorylation. In vitro experiment identified that JWBZYQ could rectify the hyperactivated Akt phosphorylation and deficient production of SHBG caused by kisspeptin54.

Conclusions: Overexpressed kisspeptin-GPR54 system inhibited SHBG synthesis in PCOS. JWBZYQ curtailed the exorbitant expression of kisspeptin and GPR54, which moderated the rise in Akt phosphorylation and subsequently promoted the production of SHBG.

Keywords

AKT phosphorylation; Jiawei Buzhong Yiqi Decoction; Kisspeptin-GPR54 system; Polycystic ovary syndrome; Sex hormone binding globulin.

Figures
Products